Role of β-Adrenergic Receptors in Stress-Induced Cardiac Injury.

IF 0.9 4区医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL

Bulletin of Experimental Biology and Medicine Pub Date : 2025-01-01 Epub Date: 2025-02-13 DOI:10.1007/s10517-025-06327-9

A A Boshchenko, B K Kurbatov, M Kilin, L N Maslov, N V Naryzhnaya, V V Saushkin, K V Zavadovsky, I V Stepanov, S V Gusakova, Yu G Birulina, T N Zaitseva, L V Smagliy

引用次数: 0

Abstract

Stress-induced cardiac injury (SICI) was modeled on female Wistar rats using a 24-h immobilization. SICI was quantified by ^99mTc-pyrophosphate accumulation in the myocardium. Blockade of β₁- and β₂-adrenergic receptors (AR) led to a decrease in SICI. β₁-AR antagonists nebivolol and atenolol almost completely prevented SICI. The selective β₂-AR antagonist ICI 118,551 increased SICI, while the selective β₃-AR antagonist L-748337 did not affect heart damage. The selective β₂-AR agonist formoterol increased cardiac tolerance to stress. These findings suggest that β₁-AR play a key role in the pathogenesis of SICI. Stimulation of β₂-AR enhances cardiac tolerance to stress. β₃-AR are not involved in the pathogenesis of SICI.

查看原文本刊更多论文

应激诱导的心脏损伤（SICI）是以雌性 Wistar 大鼠为模型，采用 24 小时固定法进行模拟的。SICI通过99m锝-焦磷酸在心肌中的积累进行量化。阻断β1-和β2-肾上腺素能受体（AR）可降低SICI。β1-AR拮抗剂奈必洛尔和阿替洛尔几乎完全阻止了SICI。选择性β2-AR拮抗剂 ICI 118,551 会增加 SICI，而选择性β3-AR拮抗剂 L-748337 不会影响心脏损伤。选择性β2-AR 激动剂福莫特罗增加了心脏对应激的耐受性。这些发现表明，β1-AR 在 SICI 的发病机制中起着关键作用。刺激β2-AR可增强心脏对应激的耐受性。β3-AR与SICI的发病机制无关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Bulletin of Experimental Biology and Medicine 医学-医学：研究与实验

CiteScore

1.50

自引率

14.30%

发文量

265

审稿时长

2 months

期刊介绍： Bulletin of Experimental Biology and Medicine presents original peer reviewed research papers and brief reports on priority new research results in physiology, biochemistry, biophysics, pharmacology, immunology, microbiology, genetics, oncology, etc. Novel trends in science are covered in new sections of the journal - Biogerontology and Human Ecology - that first appeared in 2005. World scientific interest in stem cells prompted inclusion into Bulletin of Experimental Biology and Medicine a quarterly scientific journal Cell Technologies in Biology and Medicine (a new Russian Academy of Medical Sciences publication since 2005). It publishes only original papers from the leading research institutions on molecular biology of stem and progenitor cells, stem cell as the basis of gene therapy, molecular language of cell-to-cell communication, cytokines, chemokines, growth and other factors, pilot projects on clinical use of stem and progenitor cells. The Russian Volume Year is published in English from April.